echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The application for clinical trial of the MCLA-129 injectable drug from Beda Pharmaceuticals was accepted

    The application for clinical trial of the MCLA-129 injectable drug from Beda Pharmaceuticals was accepted

    • Last Update: 2021-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 11, Beda Pharmaceuticals announced that it had received the "Notice of Acceptance" issued by the State Drug Administration (acceptance number: CXSL2100011), and that the company's application for a clinical trial of MCLAU-129 injections (hereinafter referred to as "the Clinical Trial") had been accepted by the State Drug Administration.
    MCLA-129 is a dual-specific antibody for both EGFR and c-Met targets intended for use in the treatment of patients with advanced solid tumors with EGFR or MET abnormalities.
    January 2019, the Company announced a strategic partnership with MeluS N.V. (NDAQ:MRUS, "Merus Company"), which obtained exclusive implementation licenses for the development and commercialization of MCRA-129 in China and is responsible for CMC-related work, and Merus retains all global interests outside China.
    generally speaking, patients develop access resistance after receiving EGFR inhibitors for a certain period of time, and c-Met amplification or over-expression is a common molecular biological mechanism for access resistance.
    MCLA-129 preclinical data show that MCLA-129 can be combined with NSCLC cell line with different EGFR/c-Met expression levels and different EGFR mutation types, showing good anti-tumor effect in animal solid tumor transplantation models, and good physical and pharmacological properties and safety.
    MCLA-129 is expected to effectively address EGFR inhibitor resistance caused by a variety of mechanisms, especially c-Met amplification or over-expression, with the potential to provide benefits to patients with drug-resistant NSCLC.
    As of the date of disclosure of this announcement, Amivantamab, the EGFR/c-Met dual-specific antibody of Johnson and Johnson Group Jansen, filed a Biological Product Licensing Application (BLA) and Marketing Authorization Application (MAA) with the FDA and EMA of the United States in December 2020, respectively, for the treatment of metastasis non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
    other similar drugs at home and abroad are in the pre-clinical or clinical trial stage, there is no drug on the market.
    MCLA-129 belongs to therapeutic biological products which are not listed at the domestic or foreign level, and their registration is classified as a class 1 biological products for therapeutic use.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.